FDA Accepts NDA for Medivation's (MDVN) Enzalutamide; $10M Milestone Payment Triggered

July 24, 2012 7:36 AM EDT Send to a Friend
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. announced the FDA has accepted for filing the NDA for enzalutamide (formerly MDV3100) for the potential treatment of men with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy and granted Priority Review Designation.

The FDA's acceptance of the NDA triggers a $10 million milestone payment to Medivation under its Collaboration Agreement with Astellas.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment